Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function.

Trial Profile

Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2010

At a glance

  • Drugs Betrixaban (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
    • 02 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top